All News

RheumNow Podcast square

Stop Counting Bugs (10.4.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.

Read Article
uveitis.3.jpg

Risk of Uveitis with Spondyloarthritis

Jack Cush, MD

A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can significantly lower the risk of uveitis in (SpA).

Read Article
low res disease image

Hand-Held Imaging Could Transform Arthritis Care

EurekAlert!

A new hand-held scanner developed by UCL researchers can generate highly detailed 3D photoacoustic images in just seconds, paving the way for their use in a clinical setting for the first time and offering the potential for earlier disease diagnosis.

Read Article
RheumNow Podcast square

Which One is the Loneliest Number (9.27.2024)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.

Read Article
IV,arm,intravenous,infusion

INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis

Jack Cush, MD

The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.

Read Article
FDA%20approved.jpg (keep)

Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Jack Cush, MD

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Read Article
Study of oral microbiota & psoriasis (72 PSO vs 16 healthy controls) - 16S rRNA gene sequencing of saliva found (in PSO) signif incrCapnocytandophaga, Campylobacter, Acetobacter, but decr Bacteroides, Muribaculaceae. PSA pts incr Aggregatibacter, but decr Prevotella… https://t.co/GukbWkl1Gz https://t.co/HgLcD6bP2I
Dr. John Cush RheumNow ( View Tweet)
Have a a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wvZYVbVW83 https://t.co/n26xAeU64s

Links:

Dr. John Cush RheumNow ( View Tweet)
Which One is the Loneliest Number (9.27.2024) Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer… https://t.co/c4YKKXbweX https://t.co/pEaA5qVvd9
Dr. John Cush RheumNow ( View Tweet)

CORRECTION!! UCB announced the LAUNCH of a new phase 3b BE BOLD trial - this study has no report results as yet. It WILL BE a H2H RCTcomparing bimekizumab & rizankizumab in adult #PsA pts using an ACR50 primary endpoint. Yesterday we incorrectly reported this as a completed… https://t.co/apa6VMuQTi https://t.co/BTpwo6ww7W

Dr. John Cush RheumNow ( View Tweet)
UCB released topline results of a phase 3b H2H "BE BOLD" RCT of bimekizumab (anti-IL17) vs rizankizumab (anti-IL23) in 550 active adult #PsA pts - at wk 16 inhibition of IL-17A/F was superior to IL-23 using the ACR50 primary endpoint. https://t.co/aWnHYefS2C https://t.co/2Vft5fouFv

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled data from #PsA (n=914) & #AS (n=372) RCTs looked at outcomes in smokers (37% & 48%). Current or past smoking had NO EFFECT on outcomes (MDA, ACR50, ASAS40, ASDAS), but incr odds of D/C & some SAE (SIE) but not MACE, HZ, VTE https://t.co/WRflSVO3Ig https://t.co/YMI5YCT0QK

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory… https://t.co/aITAeYuJxv https://t.co/tAPFfshPSs
Dr. John Cush RheumNow ( View Tweet)
INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis The INVIGORATE-2 trial reports that intravenous (IV) secukinumab (SEC) is both effective and safe in patients with active psoriatic arthritis (PsA), demonstrating improvements on par with subcutaneous SEC.… https://t.co/I1TVGIHByN https://t.co/WwSRQxrKAE
Dr. John Cush RheumNow ( View Tweet)
TUDOR study looked at the incidence of PsA by serially following primary care psoriasis pts. At 1 year, 14/511 developed PsA (incidence 2.74 per 100 p-yrs) and at 2 years 7/444 developed PsA (1.58/100 p-yrs). Combined incidence @2 yrs - 2.2 per 100 p-yrs https://t.co/pbHBWt0pXn https://t.co/tHMhQs1cqN

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available. Let the fun begin..... https://t.co/uNLZBqjEX0 Search by term, title or abstract # here: https://t.co/Du1eN4gA9D or Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG

Links:

Dr. John Cush RheumNow ( View Tweet)
Korean Epidemiologic study shows the prevalence of Psoriatic arthritis has increased fbetween 2008 and 2020. Prevalence was 6/1000 in 2008 & 19/1000 in 2020. PsA incidence also incr from 3.35 to 5.01/1000 in the same era https://t.co/d20zETK2q2 https://t.co/WAuqoHFDfu

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish cross-sectional survey 12 713 Inflam arthritis (RA, PsA, SpA) pts & found lonliness in one-third (RA 32%; 36% in PsA & SpA) and highest in SpA w/ depression (66%). Loneliness was correlated w/ disease activity. https://t.co/Q3IswbIwe6 https://t.co/GNohOkkmEw

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 5 Nordic registries & 29,478 RA & 10,919 PsA pts initiating 1st bDMARD,s (& 362,087 pop controls). Incident ILD was higher in RA (HR 9.7) & PsA (4.4). but MTX co-use (vs non-use) did not incr ILD in RA (HR 0.9; 0.7, 1.2) or PsA (HR 1.0) https://t.co/xY8COh85Bw https://t.co/weJGirfhDX

Links:

Dr. John Cush RheumNow ( View Tweet)
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA). https://t.co/i2w4RbGd5f https://t.co/5PD6pYB5vm

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×